Glenmark gets US regulator nod for sclerosis treatment drug

Drug firm Glenmark Pharmaceuticals today said it has received US health regulator's approval to market Riluzole tablets, used in treating nervous system disorder, in the American market. Glenmark Generics Inc, the US-based subsidiary of Glenmark Generics Ltd (GGL) has received final approval from the US Food and Drug Administration (USFDA) for Riluzole tablets in 50 mg strength, Glenmark Pharma said in a statement. The compan...